{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:41:34Z","timestamp":1789472494606,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00259-021-05456-3","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T17:02:43Z","timestamp":1623862963000},"page":"4495-4507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-6318","authenticated-orcid":false,"given":"Evyn G.","family":"Arnfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Pelecanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Latter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Pattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"5456_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"The Lancet"},{"key":"5456_CR2","doi-asserted-by":"crossref","unstructured":"Kesch C, Kratochwil C, Mier W, Kopa K and Giesel FL. Gallium-68 or fluorine-18 for prostate cancer imaging? J Nucl Med. 2017:687-8.","DOI":"10.2967\/jnumed.117.190157"},{"key":"5456_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2967\/jnumed.119.234898","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Kobe C, Hohberg M, Zlatopolskiy BD, Krapf P, Endepols H, et al. Intraindividual comparison of 18 F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61:729.","journal-title":"J Nucl Med"},{"key":"5456_CR4","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","volume":"26","author":"T Derlin","year":"2016","unstructured":"Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. (68)Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345\u201353. https:\/\/doi.org\/10.1007\/s00330-016-4308-4.","journal-title":"Eur Radiol"},{"key":"5456_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/1754-9485.12625","volume":"61","author":"N Fennessy","year":"2017","unstructured":"Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, et al. Frusemide aids diagnostic interpretation of (68) Ga-PSMA positron emission tomography\/CT in men with prostate cancer. J Med Imaging Radiat Oncol. 2017;61:739\u201344. https:\/\/doi.org\/10.1111\/1754-9485.12625.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"5456_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00259-019-04548-5","volume":"47","author":"F Haupt","year":"2020","unstructured":"Haupt F, Dijkstra L, Alberts I, Sachpekidis C, Fech V, Boxler S, et al. (68)Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging. 2020;47:624\u201331. https:\/\/doi.org\/10.1007\/s00259-019-04548-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-020-04846-3","volume":"48","author":"C Uprimny","year":"2021","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka A, et al. Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [(68)Ga]Ga-PSMA-11-PET\/CT in the evaluation of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:123\u201333. https:\/\/doi.org\/10.1007\/s00259-020-04846-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"5456_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s41181-020-00106-9","volume":"5","author":"ME Rodnick","year":"2020","unstructured":"Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, et al. Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharm Chem. 2020;5:25. https:\/\/doi.org\/10.1186\/s41181-020-00106-9.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"5456_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR11","first-page":"27","volume":"49","author":"M Debowski","year":"2019","unstructured":"Debowski M, Gulhane B, Ramsay SC, Thomas P, Garcia P, Latter M, et al. Prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Intern Med J. 2019;49:27.","journal-title":"Intern Med J"},{"key":"5456_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60:362\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.212233.","journal-title":"J Nucl Med"},{"key":"5456_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68 Ga-PSMA-11 with 18 F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and Immunohistochemical Analysis as a reference standard. J Nucl Med. 2020;61:527.","journal-title":"J Nucl Med"},{"key":"5456_CR14","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00259-018-4089-x","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Sch\u00e4fers M, B\u00f6gemann M, et al. Diagnostic performance of 18F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2055\u201361. https:\/\/doi.org\/10.1007\/s00259-018-4089-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05210-9","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05210-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher I, Kronke M, Konig M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61:51\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.229187.","journal-title":"J Nucl Med"},{"key":"5456_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","volume":"59","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS Version 1.0. J Nucl Med. 2018;59:479. https:\/\/doi.org\/10.2967\/jnumed.117.195255.","journal-title":"J Nucl Med."},{"issue":"Suppl 1","key":"5456_CR18","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"5456_CR19","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station: StataCorp LLC; 2017."},{"key":"5456_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13550-020-00745-8","volume":"11","author":"J Kuten","year":"2021","unstructured":"Kuten J, Dekalo S, Mintz I, Yossepowitch O, Mano R, Even-Sapir E. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. EJNMMI Res. 2021;11:3. https:\/\/doi.org\/10.1186\/s13550-020-00745-8.","journal-title":"EJNMMI Res"},{"key":"5456_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2967\/jnumed.118.217653","volume":"60","author":"Y Yin","year":"2019","unstructured":"Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, et al. Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories. J Nucl Med. 2019;60:511\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.217653.","journal-title":"J Nucl Med"},{"key":"5456_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578\u201383. https:\/\/doi.org\/10.1053\/hp.2000.6698.","journal-title":"Hum Pathol"},{"key":"5456_CR23","first-page":"1083","volume":"78","author":"F Lamothe","year":"1986","unstructured":"Lamothe F, Kovi J, Heshmat MY, Green EJ. Dissemination of prostatic carcinoma: an autopsy study. J Natl Med Assoc. 1986;78:1083\u20136.","journal-title":"J Natl Med Assoc"},{"key":"5456_CR24","doi-asserted-by":"publisher","unstructured":"Agheli A, Patsiornik Y, Chen Y, Chaudhry MR, Gerber H, Wang JC. Prostate carcinoma, presenting with a solitary osteolytic bone lesion to the right hip. Radiol Case Rep. 2009;4. https:\/\/doi.org\/10.2484\/rcr.v4i4.288.","DOI":"10.2484\/rcr.v4i4.288"},{"key":"5456_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/MNM.0b013e3283504528","volume":"33","author":"C Wang","year":"2012","unstructured":"Wang C, Shen Y. Study on the distribution features of bone metastases in prostate cancer. Nucl Med Commun. 2012;33:379\u201383. https:\/\/doi.org\/10.1097\/MNM.0b013e3283504528.","journal-title":"Nucl Med Commun"},{"key":"5456_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bju.15152","volume":"126","author":"MY Chen","year":"2020","unstructured":"Chen MY, Franklin A, Yaxley J, Gianduzzo T, McBean R, Wong D, et al. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020;126:396\u2013401. https:\/\/doi.org\/10.1111\/bju.15152.","journal-title":"BJU Int"},{"key":"5456_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38:200. https:\/\/doi.org\/10.1148\/rg.2018170108.","journal-title":"Radiographics"},{"key":"5456_CR28","doi-asserted-by":"publisher","unstructured":"Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, et al. 68Ga-PSMA PET\/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls. Cancer Imaging (BioMed). 2018;18. https:\/\/doi.org\/10.1186\/s40644-018-0175-3.","DOI":"10.1186\/s40644-018-0175-3"},{"key":"5456_CR29","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","volume":"44","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes L, Javadi M, Ross A, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117\u201336. https:\/\/doi.org\/10.1007\/s00259-017-3780-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.18383\/j.tom.2018.00021","volume":"4","author":"D Shetty","year":"2018","unstructured":"Shetty D, Patel D, Le K, Bui C, Mansberg R. Pitfalls in gallium-68 PSMA PET\/CT interpretation-a pictorial review. Tomography. 2018;4:182\u201393. https:\/\/doi.org\/10.18383\/j.tom.2018.00021.","journal-title":"Tomography"},{"key":"5456_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58:425\u201331. https:\/\/doi.org\/10.2967\/jnumed.116.181768.","journal-title":"J Nucl Med"},{"key":"5456_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"5456_CR33","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet. 2018;392:2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"The Lancet"},{"key":"5456_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, et al. PSMA-Based [18F]DCFPyL PET\/CT Is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411\u20139. https:\/\/doi.org\/10.1007\/s11307-016-0957-6.","journal-title":"Mol Imaging Biol"},{"key":"5456_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2214\/AJR.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310\u201320. https:\/\/doi.org\/10.2214\/AJR.10.4923.","journal-title":"AJR Am J Roentgenol"},{"key":"5456_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","volume":"44","author":"N Aide","year":"2017","unstructured":"Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17\u201331. https:\/\/doi.org\/10.1007\/s00259-017-3740-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5456_CR37","first-page":"3089","volume":"61","author":"M-T Ku","year":"2020","unstructured":"Ku M-T, Chen Y-L, Yang B-H, Huang W-S, Liu R-S. Comparison between SiPM-based and conventional PMT-based PET scanners in different reconstruction algorithm using ACR phantom. J Nucl Med. 2020;61:3089.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05456-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05456-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05456-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T01:08:33Z","timestamp":1638493713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05456-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5456"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05456-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-326201\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"13 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective audit was approved by the institutional review board of the Royal Brisbane and Women\u2019s Hospital the need for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}